MSDC-0602K has shown substantial decreases in glucose, insulin, liver enzymes, and the non-alcoholic fatty liver disease activity score (NAS) in patients with biopsy-confirmed MASH and fibrosis (F1-F3) with minimal side effects, 21 prompting a phase 3 study to assess the benefits of MSDC-0602K on glycemic control and cardiovascular outcomes in patients with pre-T2D or T2D and MASLD/MASH (NCT03970031)
Drug used to treat type 2 diabetes could reduce risk of severe COVID-19 outcomes, research suggests A type of drug used for the treatment of type 2 diabetes and obesity has been linked to a reduced risk of hospitalisation, respiratory complications, and death in people with COVID-19 who have type 2 diabetes
Always ensure you are rotating sites and using a fresh needle to minimize these risks
Weight loss alone accounts for significant mental health improvements, with studies showing self-esteem increases of up to 131% following substantial weight reduction
Glp 1 Agonists How They Work And Their Incretin Connection This article discusses Glp 1 Agonists How They Work And Their Incretin Connection
As of the time of writing, retatrutide does not have a UK marketing authorisation